At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
KRG (Korea Red ginseng) +1 moredrug
Likely dose
KRG (Korea Red ginseng) 3,000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis
In Brief
A Phase 4 clinical trial evaluating KRG (Korea Red ginseng) and Placebo (for KRG) for Fatigue. Completed, enrolled 75 participants.
Detailed Summary
Background: Korea red ginseng (KRG) has anti-carcinogenic activity, anti-oxidant activity, and cancer related anti-fatigue. Methods: Seventy five patients with non-alcoholic hepatitis were prospectively randomized to receive 3 weeks of KRG or placebo. Liver function test, pro-inflammatory cytokines, adiponectin, fatigue severity scale, and antioxidant activity were check and compared.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatigue
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
Primary CompletionApr 2012
First PostedJan 2015
TodayJul 2026
First PostedJan 6, 2015
Enrollment StartAug 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.5 years ago
Interventions
KRG (Korea Red ginseng)drug
3 weeks of KRG capsule (3,000 mg/day)
Placebo (for KRG)drug
Placebos with same shape and size were manufactured and at Korea Ginseng Corporation